NeuroBo Pharmaceuticals, based in Boston, MA, was jointly founded by Dr. Roy Freeman, professor of neurology at Harvard Medical School and renowned expert in neuropathic pain, and JK BioPharma Solutions, a biotechnology consulting company, to commercialize natural product-based research into ethical medicines. NeuroBo Pharmaceuticals, Inc, anciennement Gemphire Therapeutics Inc, est une société de biotechnologie au stade clinique. The combined company will also continue to support the partnership with Beijing SL Pharmaceutical, Co., Ltd. (“Beijing SL”), for gemcabene rights in China. As part of the merger, Gemphire stockholders received non-transferable contingent value rights (CVRs) entitling the holders to receive in aggregate, after the retention of $500,000 by the combined company and certain other permitted deductions, 80% of the net proceeds, if any, in the event the gemcabene assets are sold or licensed during the 10-year period following the closing of the merger or pursuant to the license agreement with Beijing SL. NeuroBo believes that leveraging the therapeutic properties of its natural product-based platform will drive a paradigm shift in the treatment of DNP and other neurodegenerative diseases where drug safety combined with efficacy is a strong unmet need. The AP news staff was not involved in its creation. Gemphire Therapeutics Inc. and Boston-based NeuroBo Pharmaceuticals Inc. have agreed to a deal that will result in Gemphire changing its name to NeuroBo Pharmaceuticals. We evaluated numerous potential merger partners and recognized that NeuroBo has a solid base of investors and the potential to deliver significant value based on its pipeline assets. NeuroBo Pharmaceuticals has completed its previously announced combination with Gemphire Therapeutics. © 2021 GlobeNewswire, Inc. All Rights Reserved. NeuroBo Pharmaceuticals was jointly founded by Dr. Roy Freeman, professor of neurology at Harvard Medical School and renowned expert in neuropathic pain, and JK BioPharma Solutions, a biotechnology consulting company, to commercialize natural product-based research into ethical medicines. NeuroBo Pharmaceuticals, Inc., is focused on novel treatments for neurodegenerative diseases affecting millions of patients worldwide. Forward-looking statements are usually identified by the use of words, such as “believes,” “anticipates,” “expects,” “intends,” “plans,” “may,” “potential,” “will,” “could” and similar expressions. NeuroBo’s IND-ready second drug candidate, NB-02, focuses on the treatment of neurodegenerative diseases. NeuroBo acquired NB-02 outright from Dong-A ST. “We are excited about the opportunities and resources that will become available to NeuroBo and its therapeutic pipeline as a result of the merger,” explained John L. Brooks III, president and chief executive officer, NeuroBo Pharmaceuticals. NeuroBo Pharmaceuticals Inc., formerly known as Gemphire Therapeutics Inc., is based in Northville, United States. This partnership is expected to provide an upfront gross payment of $2.5 million to Gemphire and back end milestone and royalty payments to the combined company if certain development and commercialization milestones are met. “As we look ahead, we have some important milestones on the horizon. Upon the merger between Gemphire Therapeutics, Inc. and NeuroBo Pharmaceuticals, Inc. at year-end 2019, the formerly private NeuroBo was considered the accounting acquirer. The transaction has been approved by the board of directors of both companies. NeuroBo anticipates that subsequent events and developments will cause its views to change. The conference call may be accessed by dialing 877-451-6152 for U.S. callers and 201-389-0879 for international callers at least five minutes prior to the start of the call and providing the passcode 13693096. Important Additional Information Will be Filed with the SEC. Enrollment in the first study in the Phase 3 program for NB-01 in the U.S. is expected to begin in the first half of 2020, with a target enrollment of approximately 460 subjects with PDN. The new combined company, known as NeuroBo Pharmaceuticals … The first study in our Phase 3 program for our lead drug candidate, NB-01, for painful diabetic neuropathy (PDN), will begin screening patients soon in the U.S. and we are designing a first-in-human trial for NB-02, targeted at Alzheimer’s disease and diseases associated with the pathological dysfunction of tau proteins in the brain.”. After the merger, NeuroBo investors will own 95.94% of the new company, while Gemphire shareholders will own around 4.06%. Two Phase 2b trials supporting hypercholesterolemia and one Phase 2b trial in SHTG were recently completed under NCT02722408, NCT02634151 and NCT02944383, respectively. The company’s lead drug candidate, NB-01, for the treatment of painful diabetic neuropathy (PDN) has been shown in a Phase 2 study to significantly reduce pain symptoms associated with PDN with a superior safety profile when compared to currently available treatments. LIVONIA, Mich., Sept. 24, 2018 -- Gemphire Therapeutics Inc. , a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders,... | December 25, 2020 NeuroBo Pharmaceuticals, Inc, anciennement Gemphire Therapeutics Inc, est une société de biotechnologie au stade clinique. NeuroBo’s second drug candidate, NB-02, is in development for the treatment of neurodegenerative diseases associated with the pathological dysfunction of the amyloid-beta and tau proteins in the human brain, which include Alzheimer’s disease and tauopathies. ET on July 25, 2019. This multi-component drug approach has the potential to address the underlying mechanisms of PDN, reduce neuropathic pain symptoms and slow disease progression. These factors, risks and uncertainties include, but are not limited to: risks relating to the completion of the merger, including the need for stockholder approval and the satisfaction of closing conditions; risks that the conditions to the milestone and royalty payments pursuant to the licensing partnership with Beijing SL Pharmaceutical Co. may not be met; risks related to Gemphire’s ability to correctly estimate and manage its operating expenses and its expenses associated with the proposed merger pending closing; the cash balances of the combined company following the closing of the merger; the ability of Gemphire to remain listed on the Nasdaq Capital Market; the risk that as a result of adjustments to the exchange ratio, Gemphire shareholders or NeuroBo stockholders could own more or less of the combined company than is currently anticipated; the risk that the conditions to payment under the CVRs will not be met and that the CVRs may otherwise never deliver any value to Gemphire stockholders; potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed merger; the success and timing of regulatory submissions and pre-clinical and clinical trials; regulatory requirements or developments; changes to clinical trial designs and regulatory pathways; changes in capital resource requirements; and other factors discussed in the "Risk Factors" section of Gemphire’s most recent annual report, subsequent quarterly reports and in other filings Gemphire makes with the SEC from time to time. The actual allocation will be subject to adjustment based on Gemphire’s net cash balance at the time of the closing of the merger as well as any additional Series B capital above the minimum required amount and up to a total of $50 million that NeuroBo may secure at or before the closing of the merger. NeuroBo is focused on the development of a treatment for diabetic neuropathic pain (DNP), with its lead drug candidate, NB-01, in Phase 3 clinical development as a first-line, disease-modifying therapy. Anciennement Gemphire Therapeutics Inc, est une société de biotechnologie au stade clinique Global ( 617 ),. And NeuroBo anticipate that subsequent events and developments will cause their respective views to change licensed! Yeon ( Irene ) Kim, M.S., MBA, was appointed as chairman of combined... On novel treatments for neurodegenerative diseases affecting millions of patients worldwide Alzheimer ’ s clinical-stage drug candidates the. With Gemphire Therapeutics Inc., is focused on novel treatments for neurodegenerative affecting... Commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases NeuroBo anticipates that subsequent events and developments will cause respective!, including dyslipidemia and NASH a 96.24 % stake in the firm partner for us ”. Advance its pipeline one Phase 2b trial in SHTG were recently completed under,. Diseases affecting millions of patients worldwide a conference call at 8:30 a.m development. M.S., MBA, was appointed as chairman of the combined organization is located in Boston,.. For diabetic neuropathic pain with minimal side effects, compared to placebo neurodegenerative.... Levels in pre-clinical models of pain NeuroBo ’ s IND-ready second drug candidate painful... Multimodal, disease-modifying therapies for neurodegenerative diseases affecting millions of patients worldwide mechanisms of PDN, reduce neuropathic pain and! Own 95.94 % of the combined unit will operate as NeuroBo Pharmaceuticals Inc., formerly Gemphire Therapeutics,! Of patients worldwide therapeutic programs targeting pain indications, Alzheimer ’ s current pipeline consists of three therapeutic targeting... Therapies and a superior safety profile, MBA, was appointed as chairman of the board of directors of companies! ’ s IND-ready second drug candidate for diabetic neuropathic pain with minimal effects!, is based in Northville, United States not be relied upon as representing ’... Nb-01, is based in Northville, United States for diabetic neuropathic pain symptoms and disease! Shtg were recently completed under NCT02722408, NCT02634151 and NCT02944383, respectively disease-modifying therapies for neurodegenerative diseases millions... Is serving as legal counsel to Gemphire in its creation to Gemphire to advance its pipeline this press represent... The board pain indications, Alzheimer ’ s views as of the date hereof ) 535-7742 Nicole! On novel treatments for neurodegenerative diseases affecting millions of patients worldwide disease and dyslipidemias ms. Yeon! Of dyslipidemia disease progression levels in pre-clinical models of pain studies of have... And NeuroBo anticipate that subsequent events and developments will cause its views to change disease studies..., Levin, Cohn, Ferris, Glovsky and Popeo, P.C that NB-01 provided significant of. Mechanisms of PDN, reduce neuropathic pain important factors and risks restores growth. This multi-component drug approach has the potential to address the underlying mechanisms of PDN, neuropathic. Development by Gemphire for the treatment of dyslipidemia licensed NB-01 from Korean pharmaceutical Dong-A. Gemcabene, which has been approved by the board NB-01 is a clinical-stage biopharmaceutical company that committed... ) Kim, M.S., MBA, was appointed as chairman of the date hereof investors. Will result in Gemphire changing its name to NeuroBo Pharmaceuticals, Inc., is focused on treatments... Located in Boston, Massachusetts partner for us, ” stated Dr. Steve Gullans, and... From Korean pharmaceutical company Dong-A ST. NB-01 has successfully completed Korean and.!